Kyverna Therapeutics Common Stock Alpha and Beta Analysis
| KYTX Stock | 7.93 0.66 9.08% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Kyverna Therapeutics Common. It also helps investors analyze the systematic and unsystematic risks associated with investing in Kyverna Therapeutics over a specified time horizon. Remember, high Kyverna Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Kyverna Therapeutics' market risk premium analysis include:
Beta 1.31 | Alpha 0.43 | Risk 7.95 | Sharpe Ratio 0.0854 | Expected Return 0.68 |
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Check out Kyverna Therapeutics Analysis, Kyverna Therapeutics Valuation, Kyverna Therapeutics Correlation, Kyverna Therapeutics Hype Analysis, Kyverna Therapeutics Volatility, Kyverna Therapeutics Price History and analyze Kyverna Therapeutics Performance. Kyverna Therapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Kyverna Therapeutics market risk premium is the additional return an investor will receive from holding Kyverna Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Kyverna Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Kyverna Therapeutics' performance over market.| α | 0.43 | β | 1.31 |
Kyverna Therapeutics expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Kyverna Therapeutics' Buy-and-hold return. Our buy-and-hold chart shows how Kyverna Therapeutics performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Kyverna Therapeutics Market Price Analysis
Market price analysis indicators help investors to evaluate how Kyverna Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Kyverna Therapeutics shares will generate the highest return on investment. By understating and applying Kyverna Therapeutics stock market price indicators, traders can identify Kyverna Therapeutics position entry and exit signals to maximize returns.
Kyverna Therapeutics Return and Market Media
The median price of Kyverna Therapeutics for the period between Mon, Nov 10, 2025 and Sun, Feb 8, 2026 is 8.13 with a coefficient of variation of 12.7. The daily time series for the period is distributed with a sample standard deviation of 1.03, arithmetic mean of 8.09, and mean deviation of 0.82. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Kyverna Therapeutics GAAP EPS of -0.85 misses by 0.04 | 11/13/2025 |
2 | Palo Alto, Vizsla Silver, NetEase And Other Big Stocks Moving Lower In Thursdays Pre-Market Session | 11/20/2025 |
3 | Kyverna Therapeutics Announces Positive Topline Data from Registrational KYSA-8 Trial of Miv-cel in Stiff Person Syndrome | 12/15/2025 |
4 | Kyverna Reports Positive Phase 2 Data for CAR T Therapy in Stiff Person Syndrome | 12/16/2025 |
5 | Kyverna Therapeutics Is Up 29.5 percent After Strong KYSA-8 Data And 100 Million Equity Raise | 12/17/2025 |
6 | Kyverna Therapeutics Major Shareholder Acquires 999,997.50 in Stock | 12/22/2025 |
7 | Kyverna Therapeutics Stock Up 41 percent in a Month Heres Why | 12/30/2025 |
8 | Acquisition by Christi Shaw of 185000 shares of Kyverna Therapeutics at 8.23 subject to Rule 16b-3 | 01/14/2026 |
9 | Kyverna Therapeutics Appoints Mayo Pujols as Chief Technology Officer | 02/03/2026 |
About Kyverna Therapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Kyverna or other stocks. Alpha measures the amount that position in Kyverna Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2023 | 2024 | 2025 | 2026 (projected) | Current Ratio | 3.05 | 8.61 | 7.75 | 4.19 | Net Debt To EBITDA | 0.44 | 0.71 | 0.81 | 1.33 |
Kyverna Therapeutics Investors Sentiment
The influence of Kyverna Therapeutics' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Kyverna. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Kyverna Therapeutics' public news can be used to forecast risks associated with an investment in Kyverna. The trend in average sentiment can be used to explain how an investor holding Kyverna can time the market purely based on public headlines and social activities around Kyverna Therapeutics Common. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Kyverna Therapeutics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Kyverna Therapeutics' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Kyverna Therapeutics' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Kyverna Therapeutics.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Kyverna Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Kyverna Therapeutics' short interest history, or implied volatility extrapolated from Kyverna Therapeutics options trading.
Build Portfolio with Kyverna Therapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Kyverna Stock Analysis
When running Kyverna Therapeutics' price analysis, check to measure Kyverna Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kyverna Therapeutics is operating at the current time. Most of Kyverna Therapeutics' value examination focuses on studying past and present price action to predict the probability of Kyverna Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kyverna Therapeutics' price. Additionally, you may evaluate how the addition of Kyverna Therapeutics to your portfolios can decrease your overall portfolio volatility.